4146 studies found for:    "Leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Conditions: Leukemias;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Adult T Cell Leukemia (ATL);   Chronic Myeloid Leukemia (CML-BP);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: Terameprocol (EM-1421)
2 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
3 Active, not recruiting PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Leukemia, Lymphocytyc;   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Intervention: Drug: PCI 32765
4 Terminated A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Conditions: Leukemia, Lymphoblastic, Acute, T-cell;   Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MK0752, (Notch Inhibitor)
5 Active, not recruiting Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
6 Active, not recruiting Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Hematopoietic/Lymphoid Cancer;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: carfilzomib;   Other: Cytokine Assessment;   Other: Pharmacodynamic Studies;   Other: Proteosome Inhibition Assessment;   Other: Pharmacogenomic Studies
7 Suspended Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Conditions: Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:
8 Terminated A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: Motexafin gadolinium
9 Completed Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia;   Leukemia Acute Promyelocytic Leukemia (APL);   Leukemia Acute Lymphoid Leukemia (ALL);   Leukemia Chronic Myelogenous Leukemia (CML);   Leukemia Acute Myeloid Leukemia (AML);   Leukemia Chronic Lymphocytic Leukemia (CLL)
Intervention: Procedure: Allogeneic hematopoietic cell transplantation
10 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Completed Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Leukemia;   Lymphoma
Intervention: Drug: motexafin gadolinium
12 Completed Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Conditions: Anemia;   Leukemia, Lymphocytic, Chronic;   Leukemia, Lymphocytic;   Cancer;   Neoplasms;   Quality of Life
Intervention: Drug: epoetin alfa
13 Active, not recruiting 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: 8-Chloro-Adenosine
14 Active, not recruiting 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: 5-Azacytidine
15 Withdrawn Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: Oral Clofarabine
16 Completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Leukemias of Ambiguous Lineage;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Aggressive NK-cell Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Myeloid/NK-cell Acute Leukemia;   Noncutaneous Extranodal Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
17 Terminated Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Leukemia;   Prolymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: obatoclax mesylate;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: laboratory biomarker analysis
18 Terminated Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Conditions: Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate
19 Terminated Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: Clofarabine
20 Completed
Has Results
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
Conditions: Leukemia;   CLL;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years